Despite the identification of several recent molecules in patients with infection, such as the receptor expressed on myeloid cells-1 (TREM-1), these lack specificity in sepsis pathophysiology [26] [27] [28] . Discovery of markers may add additional information, increasing the validity of clinical estimates and permitting early, aggressive, and effective sepsis therapy. This justifies every effort to further explore the paradigm of biomarkers in the area of pulmonary infections [29] . We still lack efficient tools to identify patients with CAP who are likely to develop severe complications. Current clinical severity scores partially limit these difficulties, but are far from perfect. In our study, CURB-65, APACHE II and PSI .001 demonstrated no difference between groups (fatal outcome and ARDS). Recently published studies have found that CURB-65 dose not reliably distinguish patients with pandemic influenza CAP who will have good or poor outcomes [30, 31] . In the case of PSI, this could represent its higher ability to detect mild cases; although, this could be explained by the small number of patients in our study. In contrast, we noticed that SOFA scores, although not specific for CAP, were significantly higher in non-surviving or ARDS patients. Thus, in spite of the wide variety of etiologies, this last organ dysfunction score seems to be useful in patients with CAP.